The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 52, Issue 6, 2003, Pages 731-734

  Hyun Ko, Seung ^b   Song, Ki Ho ^a   Ahn, Yu Bae ^b   Yoo, Soon Jib ^b   Son, Hyun Shik ^b   Yoon, Kun Ho ^b   Cha, Bong Yun ^b   Lee, Kwang Woo ^b   Son, Ho Young ^b   Kang, Sung Koo ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; LIPID; LIPOPROTEIN A; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DRUG EFFECT; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN ANALYSIS; HUMAN; HYPERTENSION; KOREA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ASIAN; BLOOD; ETHNOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KOREA; LIPIDS; LIPOPROTEIN(A); MALE; MIDDLE AGED; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0038142254     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00033-7     Document Type: Article

References (32)

1. Utermann G: The mysteries of lipoprotein(a). Science 246:904-910, 1989
2. Haffner SM, Morales PA, Stern MP, et al: Lp(a) concentrations in NIDDM. Diabetes 41:1267-1272, 1992
3. Chang C J, Kao JT, Wu TJ, et al: Serum lipids and lipoprotein(a) concentrations in Chinese NIDDM patients. Relation to metabolic control. Diabetes Care 18:1191-1194, 1995
4. Imperator G, Rivellese A, Galasso R, et al: Lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus and borderline hyperglycemia: A population-based study. Metabolism 44:1293-1297, 1995
5. Hiraga T, Kobayashi T, Okubo M, et al: Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 18:241-244, 1995
6. Gazzaruso C, Garzaniti A, Falcone C, et al: Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in type 2 diabetic patients and in on-diabetic subjects. Diabet Med 18:589-594, 2001
7. Mudaliar S, Henry RR: New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med 52:239-257, 2001
8. Nozue T, Michishita I, Minagawa F, et al: Troglitazone directly increases HDL cholesterol levels. Diabetes Care 22:355-356, 1999
9. Kobayashi J, Nagahima I, Hikita M, et al: Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol 47:433-439, 1999
10. Phillips LS, Grunberger G, Miller E, et al: Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes Diabetes Care 24:308-315, 2001
11. Raskin P, Rendell M, Riddle MC, et al: A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 24:1226-1232, 2001
12. Lebovitz HE, Dole JF, Patwardhan R, et al: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86:280-288, 2001
13. Gomez-Perez FJ, Aguilar-Salinas CA, Vazquez-Chavez C, et al: Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: Effects on the very-low-density and high-density lipoprotein particle distribution. Metabolism 51:44-51, 2002
14. Matsumoto K, Miyake S, Yano M, et al: Relationships between apolipoprotein(a) phenotype and increase of lipoprotein(a) by troglitazone. Metabolism 48:1-2, 1999
15. Ovalle F, Bell DS: Troglitazone's effect on lipoprotein(a) levels. Diabetes Care 22:859-860, 1999
16. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors: The Framingham study. Circulation 59:8-13, 1979
17. Hother-Nielsen O, Faber O, Sorensen NS, et al: Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care 11:531-537, 1988
18. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
19. Velazquez EM, Mendoza SG, Wang P, et al: Metformin therapay is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 46:454-457, 1997
20. Bell DS, Ovalle F: Metformin lowers lipoprotein(a) levels. Diabetes Care 21:2028, 1998
21. Plutzky J: Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol 15:416-421, 2000
22. Rosen ED, Spiegelman BM: PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731-37734, 2001
23. Lehmann JM, Moore LB, Smith-Oliver TA, et al: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956, 1995
24. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 53:409-435, 2002
25. Tack CJ, Smits P, DeMacker PN, et al: Effect of troglitazone on lipoprotein(a) levels in obese subjects. Diabetes Care 22:1752-1753, 1999
26. Nagai Y, Abe T, Nomura G: Does pioglitazone, like troglitazone, increase serum levels of lipoprotein(a) in diabetic patients? Diabetes Care 24:408-409, 2001
27. Haffner SM, Tuttle KR, Rainwater DL: Lack of change of lipoprotein (a) concentration with improved glycemic control in subjects wity type II diabetes. Metabolism 41:116-120, 1992
28. Caixas A, Perez A, Qrdonez-Llanos J, et al: Lack of change of lipoprotein(a) levels by the optimization of glycemic control with insulin therapy in NIDDM patients. Diabetes Care 20:1459-1461, 1997
29. Song KH, Ahn YB, Yoon KH, et al: The effect of long-term glycaemic control on serum lipoprotein(a) levels in patients with type 2 diabetes mellitus. Diabet Med 16:1036-1039, 1999
30. Haffner SM, Karhapaa P, Rainwater DL, et al: Insulin sensitivity and Lp(a) concentrations in normoglycemic men. Diabetes Care 18:193-199, 1995
31. Rainwater DL, Haffner SM: Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler Thromb Vasc Biol 18:1335-1341, 1998
32. Puckey LH, Knight BL: Interaction of oestrogen and peroxisome proliferator-activated receptors with apolipoprotein(a) gene enhancers. Biochem J 15:157-163, 2002